EFSA Compendium of Botanicals

Draft - work in progress

Monarda punctata L.

Family:: Lamiaceae
Approval state:: Approved
Number of articles retrieved:: 70
Number of processed references:: 2

Compositions

Endpoint Studies

Genotoxicity

Composition #1: Phillips, M. An unusual oil from Monarda punctata. journal of the american pharmaceutical association, None, p. 177–179. .

Language:

English (en)
Plant part:

Flowering top (as part-nature) (A166H)
Extraction/Preparation method:

Essential oil (as part-nature) (A166Q)
Additional extraction description:

steam distillation
Substance:

Quinones (RF-00010832-PAR)
Additional substance description:

Hydrothymoquinone
Analytical method code:

Unspecified (F598A)
Yes/No Qualitative:

Positive/Present (POS)
Result type:

Qualitative Value (Binary) (BIN)
Internal remarks:

Hydrothymoquinone

Endpoint study #1: Yamada, Keiko., Murata, Toshihiro., Kobayashi, Kyoko., Miyase, Toshio., Yoshizaki, Fumihiko. A lipase inhibitor monoterpene and monoterpene glycosides from Monarda punctata. PHYTOCHEMISTRY, 2010, vol. 71, no. 16, p. 1884–1891. DOI: 10.1016/j.phytochem.2010.08.009. [DOI link]

Study relevance:

Human health
Plant part:

Live plants (as part-nature) (A0BA0)
Preparation/Extraction method:

Solvent extraction (A0BZR)
Additional plant/substance description:

acetone–H2O (80:20)
Type of toxicological test:

in vitro (CHD061TT)
Endpoint measured:

Half maximal inhibitory concentration (CHD021EP)
Concentration unit:

Milligram/millilitre (G191A)
Effect concentration:

2
Critical effect:

Digestive (TOX18A)
Target tissue:

digestive: Pancreas (TT024A)
Effect description:

Lipase inhibition
Effect or parameter linked to the endpoint:

enzyme inhibition (CHD032BE)
Internal remarks:

Lipase inhibition